Cortex’s CEO to Present at Rodman & Renshaw’s 12th Annual Healthcare Conference on September 13, 2010

IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (OTCBB: CORX) President and CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw’s 12th Annual Healthcare Conference at 3:40 PM (EDT) on Monday, September 13, 2010 in the Fahnestock Salon at the New York Palace Hotel in New York City.

Dr. Varney will provide a brief overview of the Company’s product pipeline, clinical development status and upcoming milestones. Additional information regarding the conference can be found at http://rodmanandrenshaw.com/conferences?id=51.

To access a live audio webcast or the subsequent archived recording, log on to http://www.wsw.com/webcast/rrshq18/corx. Please connect to the website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary. An archive of the replay will be available for ninety days at http://www.cortexpharm.com.

Cortex Pharmaceuticals, Inc.

Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea. Cortex is pioneering a class of proprietary pharmaceuticals called AMPAKINE® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. For additional information regarding Cortex, please visit the Company’s website at http://www.cortexpharm.com.

Forward-Looking Statement

Note — This press release contains forward-looking statements concerning the Company’s research activities. These statements are based on the Company’s current beliefs and expectations. The success of such activities depends on a number of factors, including the risks that the Company’s proposed products may at any time be found to be unsafe or ineffective for any or all of their proposed indications. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products will require additional research, lengthy and costly preclinical and clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.